IL112288A - Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases - Google Patents

Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases

Info

Publication number
IL112288A
IL112288A IL11228895A IL11228895A IL112288A IL 112288 A IL112288 A IL 112288A IL 11228895 A IL11228895 A IL 11228895A IL 11228895 A IL11228895 A IL 11228895A IL 112288 A IL112288 A IL 112288A
Authority
IL
Israel
Prior art keywords
treatment
pct
riluzole
mitochondrial diseases
medicament
Prior art date
Application number
IL11228895A
Other languages
English (en)
Other versions
IL112288A0 (en
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IL112288A0 publication Critical patent/IL112288A0/xx
Publication of IL112288A publication Critical patent/IL112288A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL11228895A 1994-01-12 1995-01-09 Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases IL112288A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9400249A FR2714828B1 (fr) 1994-01-12 1994-01-12 Application du riluzole dans le traitement des maladies mitochondriales.

Publications (2)

Publication Number Publication Date
IL112288A0 IL112288A0 (en) 1995-03-30
IL112288A true IL112288A (en) 1999-04-11

Family

ID=9458947

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11228895A IL112288A (en) 1994-01-12 1995-01-09 Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases

Country Status (14)

Country Link
US (1) US5686475A (xx)
EP (1) EP0738147B1 (xx)
JP (1) JP3585045B2 (xx)
AT (1) ATE191342T1 (xx)
AU (1) AU1458495A (xx)
DE (1) DE69516110T2 (xx)
DK (1) DK0738147T3 (xx)
ES (1) ES2145902T3 (xx)
FR (1) FR2714828B1 (xx)
GR (1) GR3033005T3 (xx)
IL (1) IL112288A (xx)
PT (1) PT738147E (xx)
WO (1) WO1995019170A1 (xx)
ZA (1) ZA95150B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000048847A (ko) 1996-10-01 2000-07-25 스즈키 다다시 미토콘드리아 막 안정화제
US5922746A (en) * 1997-03-27 1999-07-13 Allergan Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2774908B1 (fr) * 1998-02-17 2000-06-23 Centre Nat Rech Scient Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6239156B1 (en) * 1999-04-29 2001-05-29 Centre National De La Recherche Scientifique Cnrs Method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
CA2429567A1 (en) 2000-11-22 2002-05-30 Allergan, Inc. A high-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels
US6479458B1 (en) 2001-11-08 2002-11-12 Allergan, Inc. Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
US7361478B2 (en) 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
CA2661448A1 (en) 2005-08-25 2007-03-01 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
EP2243476A1 (en) * 2009-04-17 2010-10-27 Centre National de la Recherche Scientifique Compounds for the treatment of mitochondrial diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US5236940A (en) * 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
ES2043070T3 (es) * 1988-12-15 1993-12-16 Rhone Poulenc Sante Procedimiento para la preparacion de derivados de la benzotiazolamina-2.
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
ATE191342T1 (de) 2000-04-15
DE69516110T2 (de) 2000-09-28
DK0738147T3 (da) 2000-07-10
IL112288A0 (en) 1995-03-30
ES2145902T3 (es) 2000-07-16
JP3585045B2 (ja) 2004-11-04
ZA95150B (en) 1995-09-07
EP0738147B1 (fr) 2000-04-05
PT738147E (pt) 2000-08-31
WO1995019170A1 (fr) 1995-07-20
AU1458495A (en) 1995-08-01
US5686475A (en) 1997-11-11
FR2714828B1 (fr) 1996-02-02
FR2714828A1 (fr) 1995-07-13
EP0738147A1 (fr) 1996-10-23
JPH09507498A (ja) 1997-07-29
DE69516110D1 (de) 2000-05-11
GR3033005T3 (en) 2000-07-31

Similar Documents

Publication Publication Date Title
ZA913282B (en) Dosage form
GB2284351B (en) Terfenadine metabolites and their optically pure isomers for treating allergic disorders
ATE94393T1 (de) Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
CZ176495A3 (en) The use of riluzol for preparing a medicament suitable for treating parkinson's disease and parkinson's syndromes
IL112288A (en) Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases
PL320687A1 (en) Use of incense for treating alzheimer disease
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
MY124465A (en) Reduction of infarct volume using citicoline
AU6069794A (en) Method and compositions for noninvasive dose to effect administration of lipophilic drugs
GB9421472D0 (en) Novel methods
NZ299257A (en) Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
GB9216859D0 (en) Medicaments
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
IL101163A (en) Use of flunarizine in the preparation of medicaments for treating neoplastic diseases
SE9101341D0 (sv) New medicinal use
RU2000108989A (ru) Способ профилактики и лечения респираторных болезней телят

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired